Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: Is the serum hepatitis B virus profile reliable?

Liver International

Volumn 29, Issue 8, 2009, Pages 1171-1177

  Ferraro, Donatella ^a   Pizzillo, Paola ^a   Di Marco, Vito ^a   Vultaggio, Anna ^a   Iannitto, Emilio ^a   Venezia, Giovanna ^a   Craxì, Antonio ^a   Di Stefano, Rosa ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

HBsAg seroreversion; Immunosuppression; Nested PCR; OBI

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEROCONVERSION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION; BLOOD; BLOOD DISEASE; COHORT ANALYSIS; COMORBIDITY; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMORBIDITY; DNA, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; ITALY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION;

EID: 70350059283     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02071.x     Document Type: Article

References (45)

1. Raimondo G, Allain JP, Brunetto M-A, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
2. Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-94.
3. Umeda M, Marusawa H, Seno H, et al. Hepatitis B virus infection in lymphatic tissue in inactive hepatitis B carriers. J Hepatol 2005; 42: 806-12.
4. Sagnelli E, Imparato M, Coppola N, et al. Diagnosis and clinical impact of occult hepatitis B infection in patrients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008; 80: 1547-33.
5. Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004; 72: 203-14.
6. Zerbini A, Pilli M, Boni C, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-81.
7. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
8. Ferraro D, Bonura C, Giglio M, et al. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents 2003; 17: 172-5.
9. Kao J-H, Chen P-J, Lai M-Y, Chen D-S. Occult B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
10. Squadrito G, Orlando ME, Pollicino T, et al. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 2002; 97: 1518-23.
11. Re VL III, Frank I, Gross R, et al. Prevalence, risk factors and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 315-20.
12. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-60.
13. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.
14. Hubo S, Tamori A, Ohba K, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci 2001; 46: 2408-11.
15. Chan HL, Tsang SW, Leung NW, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002; 97: 1211-5.
16. YeoW, Johnson P.J. Diagnosis, prevention and management of hepatitis B Virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
17. Lubel JS, Testro AG, Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guideline for prevention and management. Int Med J 2007; 37: 705-12.
18. Knoll A, Pietrzyk M, Loss M, GoetzWA, JilgW. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005; 79: 1631-3.
19. Rehermann B, Ferrari C, Pasquinelli C, Chiari F.V. The hepatitis B virus persist for decades after patients recovery from acute viral hepatitis despite active maintenance of a citotoxic T-lymphocite response. Nat Med 1996; 2: 1104-8.
20. Raimondo G, Navarra G,Mondella S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48: 743-6.
21. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254-8.
22. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608.
23. Hui CK, Cheng WWW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing chemotherapy. Gastroenterology 2006; 131: 59-68.
24. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
25. Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol 2006; 44(Suppl. 1): S71-6.
26. Grob P, Jilg W, Bornhak H, et al. Serological pattern 'anti- HBc alone': report on a workshop. J Med Virol 2000; 62: 450-5.
27. Torbenson M, Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
28. Pollicino T, Belloni L, Raffa, G, et al. Hepatitis B virus replication is regulated by tha acetilation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-37.
29. Hall T. Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symp Ser 1999; 41: 95-8.
30. Kumar S, Tamura K, Jakobsen IB, NeiM.Mega2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17: 1244-45.
31. Melegari M, Scaglioni PP, Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
32. Bianco E, Marcucci F, Mele A, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other thanB-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian multi-center case-control study. Italian multi-center case-control study. Haematologica 2004; 89: 70-6.
33. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-9.
34. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-7.
35. Craxi A, Laffi G, Zignego A.L. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008; 29: 85-95.
36. Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis 2005; 37: 622-7.
37. Said ZNA, El-Sayed MH, El-Bishbishi IA, et al. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. Liv Int 2009; 29: 518-24.
38. Craxi A, Tine F, Vinci M, et al. Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol 1991; 134: 641-50.
39. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky J.M. Performance of the Cobas AmpliPrep/Cobas TaqMan realtime PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008; 46: 1716-23.
40. Lo YMD, Lo ESF, Mehal WZ, et al. Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients. J Clin Pathol 1993; 46: 304-8.
41. Zanetti AR, Romano L, Zappa A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol 2006; 36(Suppl. 1): S51-5.
42. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-10.
43. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
44. Hu K.-Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis 2002; 9: 243-57.
45. Chemin I, Trepo C.Clinical impact of occult HBV infectionsJ Clin Virol 2005; 34(Suppl. 1): S15-21.